Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Thibaud Koessler*, Maria Alsina, Dirk Arnold, Irit Ben-Aharon, Manfred P. Lutz, Radka Obermannova, Mark Peeters, Francesco Sclafani, Elizabeth Smyth, Juan W. Valle, Anna Dorothea Wagner, Lucjan Wyrwicz, Elisa Fontana, Markus Moehler

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.

Original languageEnglish
Pages (from-to)911-919
Number of pages9
JournalBritish Journal of Cancer
Volume125
Issue number7
DOIs
StatePublished - 28 Sep 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group'. Together they form a unique fingerprint.

Cite this